多西紫杉醇单用或联合顺铂同步放化疗治疗中晚期下咽癌的效果对照分析

A comparative analysis of the efficacy of docetaxel alone or combined with cisplatin concurrent radiotherapy and chemotherapy in the treatment of advanced hypopharyngeal cancer

目的观察多西紫杉醇单用或联合顺铂同步放化疗治疗中晚期下咽癌的效果。方法68例中晚期下咽癌患者作为研究对象,根据治疗方案不同分为多西紫杉醇组(31例;采用同步放化疗,放疗采用根治性放疗,化疗采用多西紫杉醇进行)和多西紫杉醇+顺铂组(37例;采用同步放化疗,放疗同多西紫杉醇组,化疗采用多西紫杉醇+顺铂进行)。治疗后比较两组患者的近期临床治疗效果及不良反应发生情况;随访3年,比较两组3年生存率、复发率、远处转移率。结果多西紫杉醇+顺铂组近期临床治疗总有效率为89.19%,明显高于多西紫杉醇组的67.74%,差异具有统计学意义(P<0.05)。多西紫杉醇组患者发生不良反应24例,不良反应发生率为77.42%;多西紫杉醇+顺铂组患者发生不良反应30例,不良反应发生率为81.08%;两组患者不良反应发生率比较差异无统计学意义(P>0.05)。多西紫杉醇组患者复发率41.94%、远处转移率29.03%均明显高于多西紫杉醇+顺铂组的18.92%、8.11%,3年生存率54.84%明显低于多西紫杉醇+顺铂组的78.38%,差异均具有统计学意义(P<0.05)。结论多西紫杉醇联合顺铂同步放化疗能够提高中晚期下咽癌患者的临床疗效,且具有较好的安全性,值得临床推广。

Objective To observe the effect of docetaxel alone or combined with cisplatin concurrent radiotherapy and chemotherapy in the treatment of advanced hypopharyngeal cancer.Methods A total of 68 patients with advanced hypopharyngeal cancer were divided by different treatment methods into docetaxel group (31 cases,receiving concurrent radiotherapy and chemotherapy,radical radiotherapy and docetaxel) and docetaxel + cisplatin group (37 cases,concurrent radiotherapy and chemotherapy,radical radiotherapy and docetaxel + cisplatin).The short-term clinical,and occurrence of adverse reactions,3-year survival rate, recurrence rate and distant metastasis rate of the two groups were compared.Results Docetaxel + cisplatin group had obviously higher total short-term effective rate as 89.19% than 67.74% in docetaxel group,and the difference was statistically significant (P<0.05).Docetaxel group had 24 cases of adverse reactions,with incidence of adverse reactions as 77.42%,docetaxel + cisplatin group had 30 cases of adverse reactions,with incidence of adverse reactions as 81.08%.Both groups had no statistically significant difference in incidence of adverse reactions (P>0.05).Docetaxel group had obviously higher recurrence rate as 41.94% and distant metastasis rate as 29.03% than 18.92% and 8.11% in docetaxel + cisplatin group,and obviously lower 3-year survival rate as 54.84% than 78.38% in docetaxel + cisplatin group.Their difference was statistically significant (P<0.05).Conclusion Docetaxel combined with cisplatin concurrent chemoradiotherapy can improve the clinical efficacy of patients with advanced hypopharyngeal cancer with high safety,and it is worthy of clinical promotion.